Targeting the TLR4–MD2 axis in systemic sclerosis

Steven O’Reilly; Jacob M. van Laar

doi:10.1038/s41584-018-0077-6

Targeting the TLR4–MD2 axis in systemic sclerosis

Steven O’Reilly, Jacob M. van Laar

Applied Sciences Department

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.

Original language	English
Article number	e98850
Pages (from-to)	564-566
Number of pages	3
Journal	Nature Reviews Rheumatology
Volume	14
Issue number	10
Early online date	14 Sept 2018
DOIs	https://doi.org/10.1038/s41584-018-0077-6
Publication status	Published - 1 Oct 2018

Access to Document

10.1038/s41584-018-0077-6

Cite this

@article{a482990e36914719aa9018d73752fcfc,

title = "Targeting the TLR4–MD2 axis in systemic sclerosis",

abstract = "Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.",

author = "Steven O{\textquoteright}Reilly and {van Laar}, {Jacob M.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1038/s41584-018-0077-6",

language = "English",

volume = "14",

pages = "564--566",

journal = "Nature Reviews Rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Targeting the TLR4–MD2 axis in systemic sclerosis

AU - O’Reilly, Steven

AU - van Laar, Jacob M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.

AB - Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.

U2 - 10.1038/s41584-018-0077-6

DO - 10.1038/s41584-018-0077-6

M3 - Article

SN - 1759-4790

VL - 14

SP - 564

EP - 566

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

IS - 10

M1 - e98850

ER -

Targeting the TLR4–MD2 axis in systemic sclerosis

Abstract

Access to Document

Fingerprint

Cite this